Adjuvant ¹³¹I-metuximab in hepatocellular carcinoma: a new option for an old drug?

Lancet Gastroenterol Hepatol. 2020 Jun;5(6):517-519. doi: 10.1016/S2468-1253(20)30004-2. Epub 2020 Mar 9.

Authors

Arndt Vogel¹, Anna Saborowski²

Affiliations

¹ Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover 30625, Germany. Electronic address: vogel.arndt@mh-hannover.de.
² Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover 30625, Germany.

PMID: 32164876
DOI: 10.1016/S2468-1253(20)30004-2

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Carcinoma, Hepatocellular*
Humans
Iodine Radioisotopes
Liver Neoplasms*

Substances

Antibodies, Monoclonal
Iodine Radioisotopes
Iodine-131
metuximab